DMAC
DMAC clinical trials: DiaMedica Therapeutics Inc.
Every trial on ClinicalTrials.gov where DiaMedica Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
DMAC on the catalyst calendar · DMAC registry changes
- Primary completion Mar 16, 2022ActualPhase 2NCT04123613Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)DiaMedica Therapeutics Inc · Kidney DiseasesCompletedDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT05065216Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)DiaMedica Therapeutics Inc · Acute StrokeRecruitingDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2025Sponsor estimateNo phase registeredNCT06875141DM199 for Pregnancy ComplicationsDiaMedica Therapeutics Inc · Pre-EclampsiaWithdrawnDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 23, 2020ActualPhase 2NCT03290560Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic StrokeDiaMedica Therapeutics Inc · Acute Ischemic StrokeCompletedDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2019ActualPhase 1NCT03795389Study to Assess PK, Safety and Tolerability in Patients With DM and CKDDiaMedica Therapeutics Inc · Chronic Kidney DiseaseCompletedDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2017ActualPhase 1NCT02868996An Open Label, Phase 1b, Ascending Dose Study of DM199DiaMedica Therapeutics Inc · StrokeCompletedDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2014ActualPhase 1/Phase 2NCT01845064A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes PatientsDiaMedica Therapeutics Inc · Diabetes Type 2CompletedDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner